Neuronal LR11/SorLA expression is reduced in mild cognitive impairment

Annals of Neurology

Volumn 62, Issue 6, 2007, Pages 640-647

  Sager, Kristen L ^a   Wuu, Joanne ^a,b   Leurgans, Susan E ^b   Rees, Howard D ^a   Gearing, Maria ^a   Mufson, Elliott J ^b   Levey, Allan I ^a   Lah, James J ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Center for Neurodegenerative Disease   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; NERVE PROTEIN; PROTEIN LR11; PROTEIN SORLA; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SENILE PLAQUE; SORL1 GENE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LDL-RECEPTOR RELATED PROTEINS; MALE; MEMBRANE TRANSPORT PROTEINS; NEURONS; SENILE PLAQUES; SEVERITY OF ILLNESS INDEX; STAINING AND LABELING; TAUOPATHIES;

EID: 37149049553     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21190     Document Type: Article

References (51)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
3. Oddo S, Caccamo A, Kitazawa M, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24:1063-1070.
4. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 2006;26:1596-1603.
5. Scherzer CR, Offe K, Gearing M, et al. Loss of ApoE receptor LR11 in Alzheimer's disease. Arch Neurol 2004;61:1200-1205.
6. Jacobsen L, Madsen P, Jacobsen C, et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem 2001;276:22788-22796.
7. Andersen OM, Schmidt V, Spoelgen R, et al. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 2006;45:2618-2628.
8. Andersen OM, Reiche J, Schmidt V, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2005; 102:13461-13466.
9. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 in genetically associated with Alzheimer's disease. Nat Genet 2007;39:168-177.
10. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
11. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
12. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155.
13. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262-1270.
14. Levey A, Lah J, Goldstein F, et al. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther 2006;28:991-1001.
15. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59:198-205.
16. Bennett DA. Postmortem indices lining risk factors to cognition: results from the Religious Orders Study and the Memory and Aging Project. Alzheimer Dis Assoc Disord 2006; 20:S63-S68.
17. Bennett DA, Schneider JA, Wilson RS, et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry 2005;76: 1194-1199.
18. Mufson EJ, Chen EY, Cochran EJ, et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999;158:469-490.
19. Cochran EJ, Schneider JA, Bennett DA, Mufson EJ. Application of the NIA/Reagan Institute working criteria for the diagnosis of Alzheimer's disease to members of the Religious Orders Study. J Neuropathol Exp Neurol 1998;57:508.
20. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
21. Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999;411:693-704.
22. Chow N, Cox C, Callahan LM, et al. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc Natl Acad Sci U S A 1998;95:9620-9625.
23. Hampe W, Riedel I, Lintzel J, et al. Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. J Cell Sci 2000;113:4475-4485.
24. Cregger M, Berger A, Rimm D. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006;130:1026-1030.
25. Volpicelli LA, Lah JJ, Levey AI. Rab5-dependent trafficking of the m4 muscarinic acetylcholine receptor to the plasma membrane, early endosomes, and multivesicular bodies. J Biol Chem 2001;276:47590-47598.
26. Levene H. Robust tests for the equality of variance. In: Olkin I, ed. Contributions to probability and statistics. 5th ed. Palo Alto, CA: Stanford University Press, 1960:278-292.
27. Johnson RA, Wichern DW. Applied multivariate statistical analysis. 5th ed. Englewood Cliffs, NJ: Prentice Hall, 2002.
28. Buerger K, Teipel SJ, Zinkowski R, et al. Increased levels of CSF phosphorylated tau in apolipoprotein E [var epsilon]4 carriers with mild cognitive impairment. Neurosci Lett 2005;391: 48-50.
29. Herukka SK, Helisalmi S, Hallikainen M, et al. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 2007;28:507-514.
30. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
31. Wilson RS BL, Barnes LL, Schneider JA, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17:179-193.
32. Ikonomovic MD, Mufson EJ, Wuu J, et al. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch Neurol 2005;62:425-430.
33. Bennett DA. Update on mild cognitive impairment. Curr Neurol Neurosci Rep 2003;3:379-384.
34. Panza F, Capurso C, D'Introno A, et al. Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. Neurobiol Aging (in press).
35. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003;60:729-736.
36. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63:38-46.
37. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63:665-672.
38. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid {beta}-protein levels. Arch Neurol 2003;60:958-964.
39. McKee A, Kosik K, Kowall N. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 1991;30:156-165.
40. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid {beta}-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577.
41. Delaere P, Duyckaerts C, Brion JP, et al. Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol 1989;77: 645-653.
42. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30: 572-580.
43. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:1372-1384.
44. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990;11:29-37.
45. Motoi Y, Aizawa T, Haga S, et al. Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. Brain Res 1999;833:209-215.
46. Weeber EJ, Beffert U, Jones C, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem 2002;277:39944-39952.
47. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
48. Rami L, Molinuevo JL, Sanchez-Valle R, et al. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Int J Geriatr Psychiatry 2007;22:294-304.
49. Apostolova LG, Dinov ID, Dutton RA, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impaitment and Alzheimer's disease. Brain 2006;129:2867-2873.
50. Rasquin SM, Lodder J, Visser PJ, et al. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005;19:113-119.
51. Bozoki A, Giordani B, Heidebrink JL, et al. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001;58:411-416.